G. Nichol

486 total citations
22 papers, 380 citations indexed

About

G. Nichol is a scholar working on Oncology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, G. Nichol has authored 22 papers receiving a total of 380 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 10 papers in Immunology and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in G. Nichol's work include Cancer Immunotherapy and Biomarkers (11 papers), Immunotherapy and Immune Responses (7 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). G. Nichol is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), Immunotherapy and Immune Responses (7 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). G. Nichol collaborates with scholars based in United States, Bulgaria and United Kingdom. G. Nichol's co-authors include Kian Fan Chung, Peter J. Barnes, Michael Yellin, Jeffrey S. Weber, Steven O’Day, E. M. Hersh, John D. Powderly, Walter J. Urba, Wolfram E. Samlowski and Anne C. Pavlick and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Journal of Applied Physiology.

In The Last Decade

G. Nichol

22 papers receiving 355 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
G. Nichol United States 11 200 178 120 107 64 22 380
Els Everaert Belgium 7 25 0.1× 43 0.2× 59 0.5× 70 0.7× 67 1.0× 11 256
Hiroshi Kamoi Japan 7 43 0.2× 53 0.3× 131 1.1× 157 1.5× 102 1.6× 18 335
Xavier Duhant Belgium 5 17 0.1× 139 0.8× 99 0.8× 16 0.1× 80 1.3× 7 367
Emma Kurz United States 6 170 0.8× 134 0.8× 38 0.3× 33 0.3× 138 2.2× 11 354
Mikael Benson Sweden 12 11 0.1× 88 0.5× 280 2.3× 76 0.7× 41 0.6× 15 363
T. Talme Sweden 8 37 0.2× 75 0.4× 29 0.2× 9 0.1× 28 0.4× 14 209
Annette Cryer Germany 9 23 0.1× 60 0.3× 164 1.4× 65 0.6× 28 0.4× 10 287
M. Miralpeix Spain 7 12 0.1× 79 0.4× 43 0.4× 40 0.4× 60 0.9× 9 203
Carolina Alcantara Hirsch United States 2 112 0.6× 77 0.4× 37 0.3× 24 0.2× 65 1.0× 2 217
Lori Hayes United States 9 33 0.2× 42 0.2× 13 0.1× 26 0.2× 34 0.5× 13 183

Countries citing papers authored by G. Nichol

Since Specialization
Citations

This map shows the geographic impact of G. Nichol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Nichol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Nichol more than expected).

Fields of papers citing papers by G. Nichol

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Nichol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Nichol. The network helps show where G. Nichol may publish in the future.

Co-authorship network of co-authors of G. Nichol

This figure shows the co-authorship network connecting the top 25 collaborators of G. Nichol. A scholar is included among the top collaborators of G. Nichol based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Nichol. G. Nichol is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zeidan, Joumana, Jacob Lalezari, Martin Giedlin, et al.. (2013). CD4 reconstitution and reduction of reservoir in HIV-positive patients following a single infusion of CCR5 modified autologous CD4 T cells (SB-728-T). The Lancet. 382. S21–S21. 1 indexed citations
2.
Spencer, Andrew, Pamela G. Walker, Parisa Asvadi, et al.. (2010). A phase I study of the anti-kappa monoclonal antibody, MDX-1097, in previously treated multiple myeloma patients.. Journal of Clinical Oncology. 28(15_suppl). 8143–8143. 8 indexed citations
3.
Hersh, E., Jeffrey S. Weber, John D. Powderly, et al.. (2009). Long-term survival of patients (pts) with advanced melanoma treated with ipilimumab with or without dacarbazine. Journal of Clinical Oncology. 27(15_suppl). 9038–9038. 10 indexed citations
4.
Powderly, John D., Steven O’Day, E. M. Hersh, et al.. (2008). Prolonged survival in objective responders to ipilimumab therapy. Journal of Clinical Oncology. 26(15_suppl). 20004–20004. 1 indexed citations
5.
Urba, Walter J., Jeffrey S. Weber, Steven O’Day, et al.. (2008). Long-term survival of patients with advanced melanoma who received ipilimumab administered at 10 mg/kg every 3 weeks for 4 doses (induction dosing). Journal of Clinical Oncology. 26(15_suppl). 3018–3018. 4 indexed citations
6.
Hersh, E. M., Jeffrey S. Weber, John D. Powderly, et al.. (2008). Disease control and long-term survival in chemotherapy-naive patients with advanced melanoma treated with ipilimumab (MDX- 010) with or without dacarbazine. Journal of Clinical Oncology. 26(15_suppl). 9022–9022. 28 indexed citations
7.
Hamid, Omid, W J Urba, Michael Yellin, et al.. (2007). 7005 ORAL Ipilimumab (MDX-010) in patients with stage III/IV melanoma: kinetics and duration of response. European Journal of Cancer Supplements. 5(4). 397–397. 5 indexed citations
8.
Weber, Jeffrey S., E. Hersh, Michael Yellin, et al.. (2007). 7003 ORAL Ipilimumab (MDX-010) in patients with unresectable stage III or IV malignant melanoma: efficacy and safety data from a phase I trial. European Journal of Cancer Supplements. 5(4). 396–396. 1 indexed citations
9.
Hamid, Omid, Walter J. Urba, Michael Yellin, et al.. (2007). Kinetics of response to ipilimumab (MDX-010) in patients with stage III/IV melanoma. Journal of Clinical Oncology. 25(18_suppl). 8525–8525. 37 indexed citations
10.
Weber, Jeffrey S., E. M. Hersh, Michael Yellin, et al.. (2007). The efficacy and safety of ipilimumab (MDX-010) in patients with unresectable stage III or stage IV malignant melanoma. Journal of Clinical Oncology. 25(18_suppl). 8523–8523. 31 indexed citations
11.
Weber, Jeffrey S., Ş. Targan, Jolie Snively, et al.. (2006). Phase II trial of extended dose anti-CTLA-4 antibody ipilimumab (formerly MDX-010) with a multi-peptide vaccine for resected stages IIIC and IV melanoma. Journal of Clinical Oncology. 24(18_suppl). 2510–2510. 31 indexed citations
12.
Fischkoff, Steven, E. M. Hersh, Jeffrey S. Weber, et al.. (2005). Durable responses and long-term progression-free survival observed in a phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanoma. Journal of Clinical Oncology. 23(16_suppl). 7525–7525. 43 indexed citations
13.
Weber, Jeffrey S., et al.. (2004). A phase II, randomized multi-center study of MDX-010 alone or in combination with dacarbazine (DTIC) in stage IV metastatic malignant melanoma. Journal of Clinical Oncology. 22(14_suppl). 7511–7511. 4 indexed citations
14.
Nichol, G., Gibbe H. Parsons, & Kian Fan Chung. (1994). Effect of sodium metabisulphite on bronchial blood flow in conscious sheep: pharmacological modulation. British Journal of Pharmacology. 111(3). 918–922. 6 indexed citations
15.
Nichol, G., Brian O’Connor, J Lecomte, Kian Fan Chung, & Peter J. Barnes. (1992). Effect of neutral endopeptidase inhibitor on airway function and bronchial responsiveness in asthmatic subjects. European Journal of Clinical Pharmacology. 42(5). 491–494. 12 indexed citations
16.
Parsons, Gibbe H., G. Nichol, Peter J. Barnes, & Kian Fan Chung. (1992). Peptide mediator effects on bronchial blood velocity and lung resistance in conscious sheep. Journal of Applied Physiology. 72(3). 1118–1122. 17 indexed citations
17.
Parsons, Gibbe H., Amparo C. Villablanca, John M. Brock, et al.. (1992). Bronchial vasodilation by histamine in sheep: characterization of receptor subtype. Journal of Applied Physiology. 72(6). 2090–2098. 6 indexed citations
18.
19.
20.
Nichol, G., et al.. (1982). Phase V of the single-breath washout test. Journal of Applied Physiology. 52(1). 34–43. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Els Everaert Breakdown of academic impact, for papers by Hiroshi Kamoi Breakdown of academic impact, for papers by Xavier Duhant Breakdown of academic impact, for papers by Emma Kurz Breakdown of academic impact, for papers by Mikael Benson Breakdown of academic impact, for papers by T. Talme Breakdown of academic impact, for papers by Annette Cryer Breakdown of academic impact, for papers by M. Miralpeix Breakdown of academic impact, for papers by Carolina Alcantara Hirsch Breakdown of academic impact, for papers by Lori Hayes
Rankless by CCL
2026